Comparison of effectiveness of aspirin, clopidogrel and cilostazol monotherapy treatment in ischaemic stroke
Stroke is the third most common cause of disability and the second most common cause of death globally. Between 1990 and 2019, its prevalence increased by 70%. The prevalence of stroke increased from 7% in 2013 to 10.9% in 2018 in Indonesia. Because antiplatelet medication does not improve platelet...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2025-01-01
|
| Series: | BIO Web of Conferences |
| Online Access: | https://www.bio-conferences.org/articles/bioconf/pdf/2025/03/bioconf_ichbs2025_01001.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Stroke is the third most common cause of disability and the second most common cause of death globally. Between 1990 and 2019, its prevalence increased by 70%. The prevalence of stroke increased from 7% in 2013 to 10.9% in 2018 in Indonesia. Because antiplatelet medication does not improve platelet aggregation, ischemic stroke patients have significant death and disability rates. The efficacy of cilostazol, clopidogrel, and aspirin in ischemic stroke patients is compared in this study. 205 patients who satisfied the inclusion criteria from 919 stroke cases at RSUD Margono Soekarjo in 2023 were the subjects of a cross-sectional retrospective design using purposive sampling. The Kruskal-Wallis test and mean difference tests were used to examine the results of the therapy. Outperforming aspirin and cilostazol, clopidogrel (75 mg) were the most widely used medication (38.6%) and produced the best results, considerably enhancing PT (1 s), APTT (0.872 s), and lowering leukocytes (2.956) and platelets (3.035). Significant variations in leukocyte (p=0.045) and platelet (p=0.040) levels were found using statistical tests. When it came to enhancing coagulation markers and lowering inflammation, clopidogrel proved to be a more effective therapy option for ischemic stroke. |
|---|---|
| ISSN: | 2117-4458 |